Why 2020 could be a make-or-break year for Novavax

There may be nearly two months left of 2019, but Novavax Inc. (NASDAQ: NVAX) is already counting down to 2020. The new year promises data from a late-stage clinical trial of seasonal flu vaccine NanoFlu, which the company hopes will prove to regulators, investors and the public what it has contended all along: that it will get the product — its first — to market. The company expects results from the vaccine candidate’s phase 3 study in the first quarter of 2020, Novavax CEO Stanley Erck…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news